Cost-effectiveness analysis of peramivir and oseltamivir in treatment of influenza virus pneumonia in children

Chen Shengjie; Dai Lanfen; Li Dandan; Wang Le; Li Chengling; Jiang Chunying

doi:10.3760/j.issn.1673-4777.2019.02.014

Abstract：Objective To analyze the costs and effectiveness of peramivir and oseltamivir in the treatment of influenza virus pneumonia in children.Methods Between February 2017 and February 2018,98 children with influenza virus pneumonia were enrolled in Children's Hospital of Hebei Province.They were randomly divided into group A and group B,with 49 cases in each group.The group A was treated with intravenous peramivir and the group B took oseltamivir.Clinical effectiveness,recovery time of symptoms and signs,medication duration and hospital stay time,cost of drugs and incidence of adverse reactions were analyzed.Results There was no significant difference of the total effective rate between the group A and group B[91.8％ (45/49) vs 85.7％ (42/49)](P =0.337).Body temperature drop time,body temperature recovery time,cough disappearing time,lung rales disappearing time,medication duration and hospital stay time in the group A were significantly shorter than those in thegroupB[(1.4±0.5)dvs(2.5±0.6)d,(2.7±0.9)dvs(4.8±1.4)d,(9.0±1.3)dvs(11.5±1.8)d,(6.6±0.8)dvs (10.8±1.8)d,(3.0±0.5)dvs (4.5 ±1.1)d,(7.8±1.6)d vs (12.8 ±1.9)d](P＜0.001).Cost of drugs in the group A was significandy higher than that in the group B [(686 ± 128) yuan vs (158 ± 25)yuan] (P ＜ 0.001).Incidence of adverse reactions showed no significant difference between the two groups(P =0.766).Conclusions Peramivir and oseltamivir show similar efficacy and good safety in the treatment of influenza virus pneumonia in children.Peramivir is effective in improving clinical symptoms and reducing lengths of medication and hospital stay,but the cost is relatively high.